natgillin/translations-raw huggingface dataset:
The PRAC concluded that the risk-benefit balance of cyproterone acetate/ethinylestradiol (2mg/0.035mg) containing medicinal product(s) in the treatment of moderate to severe acne related to androgen-sensitivity (with or without seborrhea) and/or hirsutism, in women of reproductive age remains favourable subject to the restrictions, warnings, other changes to the product information, additional pharmacovigilance activities and additional risk minimisation measures agreed. 
PRAC zaključuje da omjer rizika i koristi za lijekove koji sadrže ciproteron acetat/etinilestradiol (2 mg/0,035 mg) za liječenje umjerenih do teških akni povezanih s osjetljivošću na androgene (sa seborejom ili bez nje) i/ili hirzutizma, u žena reproduktivne dobi ostaje povoljan uz ograničenja, upozorenja, druge promjene informacije o lijeku, dodatnim farmakovigilancijskim aktivnostima i dodatnim dogovorenim mjerama minimizacije rizika.
It also noted the available data concerning the hormonal contraceptive effect of CPA/EE (2mg/0.035mg) containing medicinal products. 
Također se osvrnulo na dostupne podatke za hormonski i kontracepcijski učinak lijekova koji sadrže CPA/EE (2 mg/0,035 mg).
Cyproterone acetate/ethinylestradiol (2mg/0.035mg) containing medicinal products are known to increase risk of thromboembolic events (TE). 
Poznato je da lijekovi koji sadrže ciproteron acetat/etinilestradiol (2 mg/0,035 mg) povećavaju rizik od tromboembolijskih događaja (TE).
Studies show considerable variability in their relative risk compared to non-use or other COCs and in their absolute risk for VTE. 
U apsolutnom riziku od VTE, ispitivanja pokazuju znatnu varijabilnost relativnog rizika u usporedbi s neupotrebom kontraceptiva ili drugim kombiniranim peroralnim kontraceptivima.
In this study, around 60% of women prescribed a CPA/EE-containing preparation specifically reported in the baseline questionnaire that their CPA/EE (2mg/0.035mg) prescription was due to acne and/or polycystic ovary syndrome (PCOS). 
U tom ispitivanju oko 60% žena kojima je propisan pripravak s CPA/EE, posebno je izjavilo u upitniku ispunjavanom na početku ispitivanja, da su dobile recept za CPA/EE (2 mg/0,035 mg) zbog akni i/ili sindroma policističnih jajnika (PCOS.
The PRAC in accordance with Article 107j(3) of Directive 2001/83/EC, recommended by majority that a. the marketing authorisation holders should sponsor a post-authorisation safety study together with the follow up evaluation of the results of that study, as well as a drug utilisation study (see Annex IV - Conditions of marketing Authorisations); b. the marketing authorisation holders should implement risk minimisation measures; c. the marketing authorisations of the cyproterone acetate/ethinylestradiol (2mg/0.035mg) containing medicinal products (see Annex I) should be varied (in accordance with changes to the product information as set out in Annex III). 
PRAC u skladu s člankom 107j(3) Direktive 2001/83/EZ, preporučuje većinom svojih članova da a. nositelji odobrenja trebaju sponzorirati sigurnosno ispitivanje poslije odobrenja za stavljanje lijeka u promet zajedno s praćenjem u svrhu procjene rezultata tog ispitivanja, a također i ispitivanje korisnosti lijeka (vidjeti Dodatak IV - Uvjeti davanja odobrenja);
With exception of study report AI58, no cases of VTEs or ATEs were reported in patients from the 10 MAH- sponsored clinical trials with (CPA/EE) (2mg/0.035mg). 
S izuzetkom izvješća AI58, u 10 kliničkih ispitivanja s CPA/EE koja je sponzorirao nositelj odobrenja (2 mg/0,035 mg) u bolesnika nisu zabilježeni slučajevi venske ili arterijske tromboembolije.
The protocol of drug utilisation study in order to better characterise prescribing practices for the medicinal products during typical clinical use in representative groups of prescribers and to assess main reasons for prescription should be also be submitted as part of the RMP. 
Plana potrebno je također podnijeti protokol za ispitivanje iskoristivosti lijeka kako bi se bolje opisale prakse propisivanja lijekova u uobičajenoj kliničkoj upotrebi u reprezentativnoj skupini liječnika koji propisuju lijek te radi procjene glavnih razloga propisivanja.
Overall summary of the scientific evaluation of cyproterone acetate/ethinylestradiol (2mg/0.035mg) containing medicinal product(s) by PRAC 
PRAC-ov cjelokupni sažetak znanstvene procjene lijeka koji sadrži / lijekova koji sadrže ciproteron acetat/etinilestradiol (2 mg/0,035 mg)
French assessment report February 2013 Rationale for the triggering of procedure under Article 107i of Directive 2001/83/EC on cyproterone/ethinylestradiol (2mg/0.035mg) presented by ANSM, France history of VTE before prescribing EE-containing medicinal products (e.g. combined oral contraceptives (COC)) is, therefore, recommended in the product information of the products. 
Izvješće procjene za Francusku, obrazloženje iz veljače 2013. za poticanje postupka prema članku 107i Direktive 2001/83/EZ za ciproteron/etinilestradiol (2 mg/0,035 mg) koje je podnijela Francuska agencija za lijekove (ANSM).
• The PRAC is of the opinion that the benefits of cyproterone acetate/ ethinylestradiol (2mg/0.035mg) containing medicinal products continue to outweigh the risks in the treatment of moderate to severe acne related to androgen-sensitivity (with or without seborrhea) and/or hirsutism, in women of reproductive age. 
• PRAC smatra da koristi lijekova koji sadrže ciproteron acetat/etinilestradiol (2 mg/0,035 mg) i dalje nadilazi rizike u liječenju umjerenih do teških akni povezanih s osjetljivošću na androgene (sa seborejom ili bez nje) i/ili hirzutizma u žena reproduktivne dobi.
There are two large, ongoing post-marketing surveillance studies which yield incidental data on the use of CPA/EE (2mg/0.035mg) containing medicinal products. 
U tijeku su dva velika ispitivanja nadzora nakon stavljanja lijeka u promet koje daju usputne podatke o upotrebi lijekova koji sadrže ciproteron acetat/etinilestradiol (2 mg/0,035 mg).
The PRAC is of the opinion that the benefits of CPA/EE (2mg/0.035mg) containing medicinal products continue to outweigh the risks in the treatment of moderate to severe acne related to androgen-sensitivity (with or without seborrhea) and/or hirsutism, in women of reproductive age. 
PRAC smatra da koristi od lijekova koji sadrže CPA/EE (2 mg/0,035 mg) i dalje nadilazi rizike u liječenju umjerenih do teških akni povezanih s osjetljivošću na androgene (sa seborejom ili bez nje) i/ili hirzutizma u žena reproduktivne dobi.
Compared with a corresponding reporting frequency ranging between 0.8 and 1.5 per 100,000 women-years during the previous six PSUR periods, there is no evidence of an overall increased reporting frequency of thrombotic /thromboembolic events. 
U usporedbi s odgovarajućom učestalošću prijava u rasponu od 0,8 i 1,5 na 100 000 žena-godina tijekom prethodnih 6 razdoblja
Hormone preparations containing CPA/EE (2mg/0.035mg) are part of the comparator arms in these studies. 
Hormonske pripravke koji sadrže ciproteron acetat/etinilestradiol (2 mg/0,035 mg), uzimali su dijelovi usporedbenih skupina u tim ispitivanjima.
This translates into a global spontaneous reporting rate of 1.2 non-fatal TE reports per 100,000 women-years with CPA/EE (2mg/0.035mg). 
To se prenosi u stopu globalnih spontanih prijava od 1,2 izvješća o tromboembolijskim događajima bez smrtnog ishoda na 100 000 žena-godina uz primjenu CPA/EE (2 mg/0,035 mg).
This translates into the global spontaneous reporting rate of 0.10 fatal TE reports per 100,000 womenyears with CPA/EE (2mg/0.035mg). 
To se prenosi u globalnu stopu spontanog izvještavanja od 0,10 prijava trombotskih događaja sa smrtnim ishodom na 100 000 žena-godina uz primjeni CPA/EE (2 mg/0,035 mg).
This translates into reporting rate of 1.05 ADR reports per 100,000 women-years with CPA/EE (2mg/0.035mg). 
To se prenosi u stopu globalnih izvješća od 1,05 izvješća o nuspojavama na 100 000 žena-godina za upotrebu CPA/EE (2 mg/0,035 mg).
The PRAC concluded that the benefit-risk balance of cyproterone acetate/ethinylestradiol (2mg/0.035mg) containing medicinal products is favourable as the benefits continue to outweigh the risks in the treatment of moderate to severe acne related to androgen-sensitivity (with or without seborrhoea) and/or hirsutism, in women of reproductive age. 
PRAC je zaključio da je omjer koristi i rizika za lijekove koji sadrže ciproteron acetat/etinilestradiol (2 mg/0,035 mg) povoljan, jer su koristi u liječenju umjerenih do teških akni povezanih s osjetljivošću na androgene (sa seborejom ili bez nje) i/ili hirzutizma u žena reproduktivne dobi i dalje veći od rizika.
This translates into reporting rate of 0.07 ADR reports per 100,000 women-years with CPA/EE (2mg/0.035mg). 
To se prenosi u stopu globalnih izvješća od 0,07 izvješća o nuspojavama na 100 000 žena-godina za upotrebu CPA/EE (2 mg/0,035 mg).
Levetiracetam Actavis must be taken twice a day, once in the morning and once in the evening, at about the same time each day. 
Levetiracetam Actavis se mora uzimati dva puta na dan, jednom ujutro i jednom navečer, u približno isto vrijeme svaki dan.
A risk of birth defects for your unborn child cannot be completely excluded. 
Rizik od prirođenih mana za Vaše nerođeno dijete ne može se u potpunosti isključiti.
Excipient with known effect: 
Pomoćne tvari s poznatim učinkom:
Height (cm) x ks 
visina (cm) x ks
No data are available. 
Nisu dostupni podaci.
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. 
Ako ste trudni ili dojite, mislite da biste mogli biti trudni ili planirate imati dijete, obratite se svom liječniku za savjet prije nego uzmete ovaj lijek.
Package Leaflet: Information for the patient 
Uputa o lijeku: Informacija za bolesnika
Take the number of tablets following your doctor´s instructions. 
Uzmite količinu tableta prema uputama liječnika.
Date of first authorisation: 03 October 2011 Date of latest renewal:08 September 2016 
Datum posljednje obnove odobrenja: 8.rujna 2016.
Do not take macrogol (a drug used as laxative) for one hour before and one hour after taking levetiracetam as this may result in a loss of its effect. 
Nemojte uzeti makrogol (lijek koji se koristi kao laksativ) tijekom sat vremena prije i sat vremena nakon uzimanja levetiracetama jer to može uzrokovati gubitak njegova učinka.
Contact your doctor if you took more tablets than you should. 
Obavijestite liječnika ako ste uzeli više tableta nego što ste trebali.
• limp or difficulty walking 
• šepanje ili poteškoće s hodom.
The requirements for submission of periodic safety update report for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal 
Zahtjevi za podnošenje periodičkih izvješća o neškodljivosti za ovaj lijek definirani su u referentnom popisu datuma EU (EURD popis) predviđenom člankom 107.c stavkom 7. Direktive 2001/83/EZ i svim sljedećim nadopunama objavljenima na europskom internetskom portalu za lijekove.
The major metabolic pathway (24 % of the dose) is an enzymatic hydrolysis of the acetamide group. 
Glavni je metabolički put (24% doze) enzimska hidroliza acetamidne skupine.
<1/100); rare (≥1/10,000 to <1/1,000) and very rare (<1/10,000). 
(≥1/1000 i <1/100), rijetko (≥1/10 000 i <1/1000) i vrlo rijetko (<1/10 000).
Other unidentified components accounted only for 0.6 % of the dose. 
Ostali neidentificirani metaboliti odgovaraju samo 0,6% doze.
Pharmacotherapeutic group: antiepileptics, other antiepileptics, ATC code: N03AX14. 
Farmakoterapijska skupina: antiepileptici, ostali antiepileptici, ATK oznaka: N03AX14.
One was obtained by hydroxylation of the pyrrolidone ring (1.6 % of the dose) and the other one by opening of the pyrrolidone ring (0.9 % of the dose). 
Jedan nastaje hidroksilacijom (1,6% doze), a drugi otvaranjem pirolidonskog prstena (0,9% doze).
• elevated/abnormal values in a liver function test; 
• povišene/nenormalne vrijednosti testova jetrene funkcije;
Levetiracetam is used for the epilepsy form in which the fits initially affect only one side of the brain, but could thereafter extend to larger areas on both sides of the brain (partial onset seizure with or without secondary generalisation). 
Levetiracetam se koristi za oblik epilepsije u kojem napadaji u početku zahvaćaju samo jednu stranu mozga ali bi se nakon toga mogli proširiti na veća područja obje strane mozga (parcijalni napadaji sa sekundarnom generalizacijom ili bez nje).
Due to possible different individual sensitivity, some patients might experience somnolence or other central nervous system related symptoms, especially at the beginning of treatment or following a dose increase. 
Uslijed mogućih razlika u osjetljivosti među pojedincima, u nekih bolesnika može se javiti somnolencija ili drugi simptomi vezani za središnji živčani sustav, osobito na početku liječenja ili nakon povećanja doze.
The film-coated tablets must be taken orally, swallowed with a sufficient quantity of liquid and may be taken with or without food. 
Filmom obložene tablete uzimaju se peroralno, progutaju se s dovoljnom količinom tekućine, a mogu se uzeti sa ili bez hrane.
What Levetiracetam Actavis is and what it is used for 
Što je Levetiracetam Actavis i za što se koristi
ETTEN-LEUR, 4879AC Netherlands 
ETTEN-LEUR, 4879AC Nizozemska
• A small number of people being treated with anti-epileptics such as Levetiracetam Actavis have had thoughts of harming or killing themselves. 
• Mali broj ljudi liječenih antiepilepticima kao što je Levetiracetam Actavis imali su misli o samoozljeđivanju ili samoubojstvu.
Example: if your daily dose is 1,000 mg, you might take 2 tablets of 250 mg in the morning and 2 tablets of 250 mg in the evening. 
Primjer: ako je Vaša dnevna doza 1000 mg, mogli biste uzeti 2 tablete od 250 mg ujutro i 2 tablete od
Aluminium/PVC blister packs. 
Aluminij/PVC blisteri.
• as an add-on to other antiepileptic medicines to treat: 
• kao dodatna terapija uz druge antiepileptike u liječenju:
• if you are allergic to levetiracetam, pyrrolidone derivatives or any of the other ingredients of this medicine (listed in section 6). 
• ako ste alergični na levetiracetam, derivate pirolidona ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
Therefore a 50 % reduction of the daily maintenance dose is recommended when the creatinine clearance is < 60 ml/min/1.73 m2. 
Stoga se preporučuje 50%-tno smanjenje dnevne doze održavanja ako je klirens kreatinina < 60 ml/min/1,73 m2.
• severe allergic reactions (DRESS, anaphylactic reaction [severe and important allergic reaction], 
• teške alergijske reakcije (DRESS, anafilaktička reakcija [teška i važna alergijska reakcija],
Levetiracetam has been given to you by your doctor to reduce the number of fits. 
Levetiracetam Vam je propisao Vaš liječnik kako bi se smanjio broj napadaja.
• If you notice any slow down in the growth or unexpected puberty development of your child, please contact your doctor. 
• Ako primijetite usporen rast ili neočekivan razvoj djeteta u pubertetu, obavijestite svog liječnika.
Contents of the pack and other information What Levetiracetam Actavis contains 
Sadržaj pakiranja i druge informacije Što Levetiracetam Actavis sadrži
The active substance is called levetiracetam. 
Djelatna tvar se zove levetiracetam.
Blood methotrexate and levetiracetam levels should be carefully monitored in patients treated concomitantly with the two drugs. 
Razine metotreksata i levetiracetama treba pažljivo nadzirati kod bolesnika koji se istovremeno liječe s ova dva lijeka.
Ks= 0.45 in Term infants to 1 year old; ks= 0.55 in Children to less than 13 years and in adolescent female; ks= 0.7 in adolescent male. 
ks = 0,45 za dojenčad do 1. godine života rođene u terminu; ks = 0,55 za djecu mlađu od 13 godina i za adolescente ženskog spola; ks = 0,7 za adolescente muškog spola.
The daily dose is administered in two equally divided doses. 
Dnevna doza primjenjuje se podijeljena u dvije jednake doze.
The apparent body weight adjusted clearance was approximately 30 % higher than in epileptic adults. 
Prividni tjelesni klirens korigiran za tjelesnu težinu bio je približno 30% veći nego u odraslih s epilepsijom.
Should your doctor decide to stop your Levetiracetam Actavis treatment, he/she will instruct you about the gradual withdrawal of Levetiracetam Actavis. 
Ako Vaš liječnik odluči prekinuti Vaše liječenje Levetiracetamom Actavis, on/ona uputit će Vas da postupno prekinete uzimanje Levetiracetama Actavis.
When you will first start taking Levetiracetam Actavis, your doctor will prescribe you a lower dose (500 mg each day) during 2 weeks before giving you the lowest general dose of 1,000 mg. 
Kad prvi put počnete uzimati Levetiracetam Actavis, liječnik će Vam propisati manju dozu (500 mg svaki dan) tijekom 2 tjedna prije davanja najmanje uobičajene doze od 1000 mg.
Levetiracetam has minor or moderate influence on the ability to drive and use machines. 
Levetiracetam ima manji ili umjereni utjecaj na sposobnost upravljanja vozilima i rada sa strojevima.
Talk to your doctor before taking Levetiracetam Actavis 
Obratite se svom liječniku prije nego uzmete Levetiracetam Actavis
Mogilska 80, 31-546 Kraków, Poland 
Mogilska 80. 31-546 Krakow, Poljska
Do not use this medicine after the expiry date which is stated on the carton, label or blister after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji, naljepnici ili blisteru iza oznake „EXP“.
The major route of excretion was via urine, accounting for a mean 95 % of the dose (approximately 93 % of the dose was excreted within 48 hours). 
Levetiracetam se uglavnom izlučuje putem urina, i to 95% doze (približno 93% doze izluči se za 48 sati).
In addition, 101 infants aged less than 12 months have been exposed in a post authorization safety study. 
Pored toga, 101 dojenče mlađe od 12 mjeseci bilo je izloženo lijeku u postmarketinškim ispitivanjima
30 tablets 100 tablets 200 tablets 
30 tableta 100 tableta 200 tableta
The cumulative urinary excretion of levetiracetam and its primary metabolite accounted for 66 % and 24 % of the dose, respectively during the first 48 hours. 
Kumulativno izlučivanje levetiracetama i njegovog glavnog metabolita urinom iznosi 66% odnosno 24% doze tijekom prvih 48 sati.
What Levetiracetam Actavis looks like and contents of the pack 
Kako Levetiracetam Actavis izgleda i sadržaj pakiranja
Epilepsy is a condition where the patients have repeated fits (seizures). 
Epilepsija je stanje kod kojeg bolesnik ima ponovljene napadaje.
How to store Levetiracetam Actavis Contents of the pack and other information 
Kako čuvati Levetiracetam Actavis Sadržaj pakiranja i druge informacije
Add-on therapy for infants aged from 1 month to less than 6 months 
Dodatna terapija za dojenčad u dobi od 1 mjeseca do manje od 6 mjeseci
Therefore, the interaction of Levetiracetam Actavis with other substances, or vice versa, is unlikely. 
Iz toga proizlazi da interakcija lijeka Levetiracetam Actavis s drugim tvarima, i obrnuto, nije vjerojatna.
If you take more Levetiracetam Actavis than you should 
Ako uzmete više lijeka Levetiracetam Actavis nego što ste trebali
It is therefore recommended to adjust the maintenance daily dose of Levetiracetam Actavis, based on creatinine clearance in patients with moderate and severe renal impairment (see section 4.2). 
Stoga se preporučuje prilagođavanje dnevne doze održavanja lijeka Levetiracetam Actavis s obzirom na klirens kreatinina u bolesnika s umjerenim i teškim oštećenjem bubrega (vidjeti dio 4.2).
The active substance, levetiracetam, is a pyrrolidone derivative (S-enantiomer of α-ethyl-2-oxo-1-pyrrolidine acetamide), chemically unrelated to existing antiepileptic active substances. 
Djelatna tvar, levetiracetam, jest derivat pirolidona (S-enantiomer α-etil-2-okso-1-pirolidin acetamida), kemijski različit od postojećih antiepileptičnih djelatnih tvari.
In all of the above cases an oral solution should be used. 
U svim tim slučajevima treba upotrijebiti oralnu otopinu.
The CLcr in ml/min may be estimated from serum creatinine (mg/dl) determination, for adults and adolescents weighing 50 kg or more, using the following formula: 
Klirens kreatinina u ml/min može se procijeniti iz serumskog kreatinina (mg/dl), za odrasle i adolescente teške 50 kg ili više, pomoću sljedeće formule:
No new safety concerns for levetiracetam were identified for infants less than 12 months of age with epilepsy. 
Nisu identificirane nove sigurnosne bojazni za dojenčad mlađu od 12 mjeseci koja boluje od epilepsije.
• a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome); 
• rasprostranjeni osip s mjehurićima i kožom koja se ljušti, posebice oko usta, nosa, očiju i genitalija (Stevens-Johnsonov sindrom)
Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to 
Nuspojave su prikazane prema opadajućoj ozbiljnosti i njihova je učestalost definirana na sljedeći način: vrlo često (≥1/10), često (≥1/100 i <1/10), manje često
35 infants aged less than 1 year with partial onset seizures have been exposed in placebo-control clinical studies of which only 13 were aged < 6 months. 
Trideset i pet dojenčadi mlađe od godine dana s parcijalnim napadajima bili su izloženi lijeku u placebom kontroliranim kliničkim ispitivanjima od kojih su samo njih 13 bili mlađi od 6 mjeseci.
In addition, the available dose strengths of the tablets are not appropriate for initial treatment in children weighing less than 25 kg, for patients unable to swallow tablets or for the administration of doses below 250 mg. 
Ujedno, dostupne doze tableta nisu prikladne za početak liječenja u djece lakše od 25 kg, u bolesnika koji ne mogu gutati tablete ili za davanje doza manjih od 250 mg.
* The colourants are: 
*Bojila su:
Other medicines and Levetiracetam Actavis 
Drugi lijekovi i Levetiracetam Actavis
Therefore, there is no need for plasma level monitoring of levetiracetam. 
Stoga nije potrebno praćenje razine levetiracetama u plazmi.
Concomitant administration of levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels. 
Zabilježeno je da istovremena primjena levetiracetama i metotreksata smanjuje kliren metotreksata što rezultira u povećanoj/produljenoj koncentraciji metotreksata u krvi do potencijalno toksičnih razina.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Carton for Aluminium/PVC blisters 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU Kutija za aluminij/PVC blistere
In most subjects with severe hepatic impairment, the clearance of levetiracetam was reduced by more than 50 % due to a concomitant renal impairment (see section 4.2). 
U većine osoba s teškim oštećenjem jetre klirens levetiracetama smanjen je za više od 50% uslijed popratnog oštećenja bubrega (vidjeti dio 4.2).
250 mg tablet: Indigo carmine (E132). 
250 mg tableta: indigo carmine (E132).
The adverse reaction profile presented below is based on the analysis of pooled placebo-controlled clinical trials with all indications studied, with a total of 3,416 patients treated with levetiracetam. 
Profil nuspojave opisan niže temelji se na analizi zbirnih placebom konroliranih kliničkih istraživanja za sve ispitivane indikacije, u kojima je levetiracetamom liječeno ukupno 3416 bolesnika.
Perforated unit dose blisters: 60 x 1 film-coated tablets (only available for 250 mg, 500 mg and 1,000 mg tablets). 
Perforirani blisteri djeljivi na jedinične doze: 60 x 1 filmom obloženih tableta (dostupni samo za tablete od 250 mg, 500 mg i 1000 mg).
An oral solution is a formulation more appropriate to infants and children under the age of 6 years and to children and adolescents (from 6 to 17 years) weighing less than 50 kg and when tablets do not allow accurate dosage. 
Oralna otopina je prikladnija formulacija za primjenu u dojenčadi i djece mlađe od 6 godina i za djecu i adolescente (od 6 do 17 godina) koja teže manje od 50 kg i kada tablete ne dozvoljavaju točno doziranje.